Skip to content

The Effect of Chiropractic Plus Nutritional Supplement in Patients With Chronic Pain and Inflammation.

The Effect of Co-therapy Chiropractic Plus Nutritional Supplement in Patients Experiencing Chronic Pain and Inflammation.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05743855
Enrollment
25
Registered
2023-02-24
Start date
2019-03-28
Completion date
2022-04-01
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Inflammatory Response

Brief summary

Evaluating the effect of a combined therapy of chiropractic sessions plus nutritional supplement containing hemp, omega-3 fatty acids, and broccoli extract oil in patients experiencing chronic pain and inflammation.

Interventions

DIETARY_SUPPLEMENTNutritional Supplement

Nutritional Supplement + Chiropract sessions

OTHERPlacebo

Placebo + Chiropractic sessions

Sponsors

Standard Process Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Chronic pain (\>3years)

Exclusion criteria

* GABA/opioid medication

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Pain level using the Brief Pain Inventory (BPI) after 12 weeks.Baseline and 12 weeksThe BPI is a validated self-reporting instrument assessing pain. Possible score range 0-10 with higher scores indicating higher pain levels. The instrument contains 9 items.
Change from baseline in Pain intensity using the 11-Point Numeric Rating Scale (11-NRS) after 12 weeks.Baseline and 12 weeksThe 11-NRS is a validated self-reporting instrument assessing pain level. Possible score ranges from '0' representing no pain to '10' representing worst pain imaginable.

Secondary

MeasureTime frameDescription
Reactive oxygen species (ROS) statusAt baseline and after 12 weeksReactive oxygen species (ROS) status in the peripheral blood mononuclear cells was used to assess participant's inflammation biomarkers.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026